Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2023 14:00 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,408 restricted stock units to employees of the Company as well...
January 24, 2023 06:27 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24,...
January 19, 2023 11:00 ET | Source: Genmab A/S

Correction to Company Announcement No. 1 of January 3, 2023

Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in...
January 03, 2023 12:31 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; January 3, 2023 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
January 02, 2023 07:56 ET | Source: Genmab A/S

Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41st Annual J.P. Morgan...
December 21, 2022 07:00 ET | Source: Genmab A/S

Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Media Release COPENHAGEN, Denmark; December 21, 2022 JNDA submission supported by results of Japanese and global phase 2 clinical trials evaluating epcoritamab in patients with mature B-cell...
December 14, 2022 15:20 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; December 14, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
December 13, 2022 15:05 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; December 13, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
December 13, 2022 14:58 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; December 13, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 74,849 shares as a consequence of the exercise of employee warrants. The...
December 12, 2022 08:23 ET | Source: Genmab A/S

Genmab to Hold 2022 R&D Update and ASH Data Review Meeting

Media Release Event to be held live in New Orleans, LouisianaMeeting to be webcast live and archived on www.genmab.com Copenhagen, Denmark; December 12, 2022 – Genmab A/S (Nasdaq: GMAB) will hold...